Research on immune checkpoint inhibitors as a treatment option for bladder cancer is ongoing, with some studies suggesting potential benefits, including improved outcomes for patients with high-risk bladder cancer. The role of immunotherapy in treating bladder cancer is being refined, with possible applications including use after surgery and in combination with other treatments. The field is seeing advances and updates on various approaches, including new therapies and combinations, although the current state of evidence is still being explored.